Table 2 Reduction in endotoxin activity, Interleukin-6, procalcitonin and HMGB-1 over time
Intervention arm | Filter intervention | p—over groups | p—over timepoints | |||
|---|---|---|---|---|---|---|
0 h | 24 h | 48 h | 72 h | |||
A. Reduction in endotoxin activity [%] | 0.82 | < 0.01 | ||||
Standard of care | 0 | 16 [10–28] | 2 [− 18–21] | 12 [1–42] | ||
oXiris | 0 | 2 [− 18–21] | 32 [− 8–53] | 21 [10–51] | ||
Toraymyxin | 0 | 12 [1–42] | 15 [− 4–34] | 23 [10–36] | ||
B. Reduction in Interleukin-6 [%] | 0.58 | < 0.001 | ||||
Standard of care | 0 | 57 [43–74] | 77 [61–85] | 80 [59–91] | ||
oXiris | 0 | 75 [28–86] | 83 [71–96] | 96 [91–98] | ||
Toraymyxin | 0 | 66 [31–82] | 81 [65–95] | 85 [48–95] | ||
C. Reduction in Procalcitonin [%] | 0.16 | < 0.01 | ||||
Standard of care | 0 | − 9 [− 38–29] | 34 [11–50] | 60 [42–68] | ||
oXiris | 0 | 31 [− 5–53] | 60 [34–75] | 71 [27–81] | ||
Toraymyxin | 0 | 11 [− 55–34] | 25 [− 56–62] | 18 [− 15–71] | ||
D. Reduction in High-Mobility-Group-Protein B1 [%] | 0.68 | 0.46 | ||||
Standard of care | 0 | 12 [− 7–21] | 30 [− 15–52] | 32 [− 4–50] | ||
oXiris | 0 | 23 [− 2–44] | 24 [3–31] | 37 [14–62] | ||
Toraymyxin | 0 | 15 [− 18–24] | 24 [− 25–27] | 21 [− 47–29] | ||